Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Revolution Medicines Inc RVMD

Alternate Symbol(s):  RVMDW

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS... see more

Current News (NDAQ:RVMD)

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

GlobeNewswire 7 days ago

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 10 days ago

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

GlobeNewswire December 18, 2025

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

GlobeNewswire November 5, 2025

Revolution Medicines to Participate in November 2025 Investor Conferences

GlobeNewswire November 4, 2025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

GlobeNewswire October 29, 2025

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

GlobeNewswire October 27, 2025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

GlobeNewswire October 22, 2025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

GlobeNewswire October 16, 2025
View More News ››

Opinion & Analysis (NDAQ:RVMD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RVMD)

Be the first to post on this bullboard.

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc., together with its subsidiaries, engages in the design, engineering, manufacture, testing, and distribution of ...
View More »

Podcasts